Matches 1 - 50 out of 178 1 2 3 4 >


Match Document Document Title
US20150079001 IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA  
The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of...
US20130302248 Imaging Agents for Detecting Neurological Disorders  
Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formula (I) capable of binding to tau proteins and...
US20130028837 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING  
The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds...
US20120276007 IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA  
The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of...
US20100172836 SYNTHESIS OF 18F-RADIOLABELED STYRYLPYRIDINES FROM TOSYLATE PRECURSORS AND STABLE PHARMACEUTICAL COMPOSITIONS THEREOF  
The present invention relates to methods of synthesizing 18F-radiolabeled styrylpyridine and its tosylate precursor. The present invention further relates to stable pharmaceutical compositions...
US20080213178 Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid  
The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is...
US20160271277 Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders  
The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective...
US20160256534 METHODS OF TREATING PARKINSON'S DISEASE USING VIRAL VECTORS  
Methods of delivering viral vectors, particularly recombinant adeno-associated virus (rAAV) virions, to the central nervous system (CNS) using convection enhanced delivery (CED) are provided. The...
US20080193380 Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy  
Provided is a class of radiolabeled androgen receptor targeting agents (ARTA), useful for prostate cancer imaging and in treating or preventing prostate cancer. The agents define a new subclass of...
US20080095702 Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid  
The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is...
US20160166550 Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders  
The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective...
US20120189548 2-ARYLPYRAZOLO[L,5-ALPHA]PYRIMIDIN-3-YL ACETAMIDE DERIVATIVES AS LIGANDS FOR TRANSLOCATOR PROTEIN (18 KDA)  
The invention provides compounds of formula (I) radiolabelled with 18F, 123I, 76Br, 124I or 75Br and salts thereof, and a method of imaging translocator protein (18 kDa) (TSPO) in a subject...
US20170096390 FLUORINATED 2-AMINO-4-(BENZYLAMINO)PHENYLCARBAMATE DERIVATIVES  
The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel...
US20090311179 Selective Targeting of Apoptotic Cells  
The invention relates to a method of selectively targeting an active agent (or agent capable of becoming an active agent) to apoptotic cells in a vertebrate, comprising administering to said...
US20080247948 STEREOISOMERS OF FATTY ACID ANALOGS FOR DIAGNOSTIC IMAGING  
The present invention provides novel imaging agents for clinical diagnosis of injuries and diseases, in the form of a radionuclide in spatial proximity to a substantially pure stereoisomer of a...
US20150098903 Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders  
One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In...
US20160009691 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS  
The invention provides a chemical entity of Formula (I), and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic...
US20130011336 IMAGING AGENTS OF FIBROTIC DISEASES  
Agents and methods for imaging a cell and/or a portion of tissue characterized by fibrosis, as well as to agents and methods for determining and/or diagnosing fibrotic diseases are disclosed...
US20100143253 COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES  
The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by...
US20080056991 PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES  
Substituted piperazinyl and diazepanyl benzamides and benzthioamides of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.
US20160030605 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS  
Compounds of Marlush formula (I) described in the claims are useful in diagnostic methods for detecting and/or identifying cells presenting PSMA. Disclosed are also methods for preparing the...
US20140227184 C-HALOGEN BOND FORMATION  
Methods of halogenating a carbon containing compound having an sp3 C—H bond are provided. Methods of fluorinating a carbon containing compound comprising halogenation with Cl or Br followed by...
US20130089502 PET RADIOPHARMACEUTICALS FOR DIFFERENTIAL DIAGNOSIS BETWEEN BILATERAL AND UNILATERAL CONDITIONS OF PRIMARY HYPERALDOSTERONISM  
A functional PET imaging method is disclosed for differentiation between bilateral hyperplasia and unilateral adenoma comprising (1) introducing a radioactively labelled CYP11 B2 (aldosterone...
US20110165076 NOVEL [F-18]- LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), USE THEREOF AND METHOD FOR THEIR PRODUCTION  
What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use.
US20110104057 Novel [F-18]-labelled L-glutamic acid and L-glutamine derivatives (II), their use and processes for their preparation  
What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use.
US20090060838 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES  
Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable salts, their synthesis and labeling, pharmaceutical compositions containing them, and their use in the...
US20130064770 RADIOLABELED COMPOUNDS AND METHODS THEREOF  
The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in...
US20100254902 STABILIZATION OF RADIOPHARMACEUTICALS  
The invention relates to stabilised radiopharmaceutical compositions which comprise: (i) an 18F-labelled compound; (ii) an effective stabilizing amount of gentisic acid or a salt thereof with a...
US20140105820 AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES  
The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or...
US20130209363 METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS  
This invention relates to methods, which provide access to [F-18]fluoropegylated (aryl/heteroaryl vinyl)-phenyl methyl amine derivatives.
US20110286922 IMAGING AND RADIOTHERAPY METHODS  
The present invention relates to in vivo imaging and radiotherapeutic methods and agents which target the enzyme aldehyde dehydrogenase (ALDH) and that are suitable for the in vivo imaging of...
US20090035215 RADIOFLUORINATION  
The present invention relates to novel compounds suitable for or already radiolabeled with 18F, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled...
US20130129625 IN VIVO IMAGING AGENTS  
The present invention relates to the field of medical imaging, and in particular to imaging of disease states associated with the upregulation of the chemokine receptor 5 (CCR5). Imaging agents,...
US20130129626 IN VIVO IMAGING AGENTS  
The present invention relates to the field of medical imaging, and in particular to imaging of disease states associated with the upregulation of the chemokine receptor 5 (CCR5). Imaging agents,...
US20090252680 NOVEL COMPOUND WITH AFFINITY FOR AMYLOID  
A compound represented by the following formula or a salt thereof: wherein each of A1, A2, A3 and A4 independently represents a carbon or nitrogen; R1 is a group selected from the group consisting...
US20120219500 DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES  
A diagnostic agent for infectious diseases which is capable of distinguishing among different kinds of bacterial species and which allows simple and non-invasive measurement and/or imaging in a...
US20080292552 Pet Radiotracers  
The invention relates to novel 18F-labelled compounds which may be suitable for use as Positron Emission Tomography (PET) radiotracers, and to processes for preparation of such. The 18F-labelled...
US20150231249 18F-FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS  
The present invention provides a pharmaceutical composition comprising [18F]FACBC having certain advantages over known compositions comprising [18F]FACBC. Also provided by the present invention is...
US20110293520 NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES  
The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of...
US20160228586 Compounds and Their Use for Preparation of Tau Imaging Agents and Tau Imaging Formulations  
The present invention provides novel trimethylammonium compounds, of the Formula: (I) methods of making these compounds, methods of using the compounds for preparation of tau imaging agents, and...
US20150030540 Imaging agents for detecting neurological dysfunction  
Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective...
US20130224114 Translocator Protein Ligands  
The present invention relates to compounds and methods for imaging translocator protein (18 kDa) (TSPO) expression in a subject. This invention also relates to compounds and methods for the...
US20130164217 METHOD OF DIAGNOSING, PREVENTING AND/OR TREATING DEMENTIA & RELATED DISORDERS  
Described are assay methods, modules and kits useful in the detection, treatment and/or prevention of dementia and related conditions, including but not limited to Alzheimer's disease and mild...
US20120328521 FORMULATIONS SUITABLE FOR PET IMAGING WITH HYDROPHOBIC PET AGENTS  
The invention is directed to formulations of lipophilic Amyloid βeta ligand stilbene based derivatives and more particularly to formulations which are administrable parentally e.g. intravenously...
US20100226853 Fluorine-18 derivatives of dasatinib and uses thereof  
Provided herein are [18F]-labeled compounds having a chemical structure: R1 is 18F, 1-piperazinyl-4-CH2CH2—18F or 1-piperazinyl-4-CH2CH2OCH2CH2—18F, R2 is CH3 or 18F and R3 is Cl or 18F, such that...
US20120039803 PRETARGETING KIT, METHOD AND AGENTS USED THEREIN  
Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal...
US20110208064 Curcumin Derivatives for Amyloid-Beta Plaque Imaging  
The present invention provides curcumin-derived near infrared (NIR) imaging probes. Upon interacting with amyloid β aggregates, these probes undergo a range of changes, qualifying them as “smart”...
US20150139903 PHOSPHODIESTERASE 1-TARGETING TRACERS AND METHODS  
Tracers targeting phosphodiesterase1 for use in gamma radiation detection-based diagnostic techniques, particularly gamma-emitter labeled tracers for SPECT and positron emitter-labeled...
US20120189547 [18F] LABELLED ANALOGUES OF FLUMAZENIL AS IN VIVO IMAGING AGENTS  
The present invention provides radiofluorinated compounds useful for in vivo imaging GABAA receptors. Also provided by the present invention is a method of synthesis for the radiofluorinated...
US20120121509 VITAL FLUOROCHROME CONJUGATES AND METHODS OF USE  
The present invention provides compositions and methods based on vital fluorochrome conjugates that are useful for imaging dying and dead cells.

Matches 1 - 50 out of 178 1 2 3 4 >